PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ascpBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleAddiction Science & Clinical Practice
 
Addict Sci Clin Pract. 2008 June; 4(2): 28–35.
PMCID: PMC2797110

The Search for Medications to Treat Stimulant Dependence

Abstract

Progress in understanding the neurobiology of stimulant dependence has enabled researchers to identify medications whose pharmacological effects suggest that they might help patients initiate abstinence or avoid relapse. Several of these medications and a vaccine have shown encouraging results in controlled clinical trials with cocaine-dependent patients. The search for a medical treatment for methamphetamine dependence started more recently, due to the later emergence of this epidemic, but at least one candidate medication has shown promise in early clinical testing. Treatment approaches that combine efficacious medications and empirically proven behavioral interventions, such as voucher-based reinforcement therapy, will almost certainly produce the best results.

The demand for treatment for cocaine dependence remained roughly level from 1992 to 2005, while the demand for treatment for amphetamine dependence increased about eight-fold (Substance Abuse and Mental Health Services Administration, 2006). Although progress has been made in developing new psychosocial treatments for stimulant dependence, many patients do not substantially benefit from psychotherapy alone. Dropout rates in cocaine dependence treatment programs frequently exceed 50 percent (Alterman et al., 1996). Thus, the identification of medications to augment psychosocial treatment is an urgent research priority. Progress in understanding the neurobiology of stimulant dependence has led to the identification of several medications whose effects counter or alleviate the disordered processing that underlies patients’ symptoms. Depending on their specific actions, these medications may help patients attain an initial period of abstinence or avoid relapse (Table 1). Although none has yet been approved for treating stimulant dependence, several have shown encouraging results in controlled clinical trials.

TABLE 1
Candidate Medications for Stimulant Dependence

ABSTINENCE INITIATION

Cocaine withdrawal symptoms, including dysphoric mood, fatigue, sleep disturbance, appetite changes, and irritability, contribute to many dependent patients’ difficulties quitting the drug. Several studies have demonstrated that patients who experience severe cocaine withdrawal symptoms, as measured by the Cocaine Selective Severity Assessment (CSSA), are twice as likely to drop out of treatment and less likely to attain abstinence in outpatient programs (Kampman et al., 2001). An apparent clinical basis for these associations is that patients who are subject to severe symptoms may keep taking the drug to avoid them. Investigators also have noted that these individuals report more intense highs from experimentally administered cocaine (Sofuoglu et al., 2003; Figure 1) and therefore may experience greater drive to keep taking it.

FIGURE 1
A Tighter Vise

Modafinil

The most promising medication for abstinence initiation is modafinil, a medication currently approved for the treatment of narcolepsy. Modafinil has several characteristics that might facilitate abstinence from cocaine. As a mild stimulant, it may reduce cocaine withdrawal symptoms (Dackis and O’Brien, 2003). As an enhancer of glutamate neurotransmission, it may ameliorate the glutamate depletion seen in chronic cocaine users (Dackis and O’Brien, 2003); improved baseline glutamatergic tone in the nucleus accumbens prevented reinstatement of cocaine self-administration in an animal model of relapse (Baker et al., 2003).

Modafinil has been shown to block the euphoric effects of cocaine in three independent human laboratory studies. In the first, pretreatment with 400 mg of modafinil blunted euphoria from a subsequent intravenous dose of cocaine (30 mg) when compared with pretreatment with 200 mg of modafinil or placebo (Dackis et al., 2003). In a similar study, patients given 400 or 800 mg of modafinil reported lower ratings of “high,” “any drug effect,” and “worth in dollars” in response to a subsequent dose of cocaine, compared with patients who received cocaine alone (Malcolm et al., 2006). Most recently, Hart and colleagues (2008) evaluated the effect of modafinil maintenance (200 or 400 mg/day) on eight non-treatment-seeking cocaine-dependent individuals’ responses to smoked cocaine (at 0, 12, 25, and 50 mg). Modafinil at both dosages attenuated the participants’ frequency of self-administration, subjective ratings of cocaine’s effects, and cocaine-related increases in heart rate and blood pressure.

Modafinil improved cocaine abstinence rates in two clinical trials. In a double-blind pilot trial with 62 cocaine-dependent patients, those who received modafinil submitted more cocaine-metabolite-free urine samples than placebo-treated patients (42 vs. 22 percent; Dackis et al., 2005). Modafinil-treated patients were also deemed more improved on the clinician-rated portion of the Clinical Global Impression Scale (CGIS). The results of the pilot trial were replicated in a recent multicenter trial. Over 16 weeks, 210 cocaine-dependent patients took 200 mg of modafinil daily, 400 mg of modafinil daily, or placebo. Among patients who were dependent only on cocaine, both dosages of modafinil were superior to placebo for promoting abstinence (Dackis, 2007). This trial also included patients (41 percent) who were dually dependent on cocaine and alcohol; their abstinence rates were not increased by modafinil. Two more large-scale double-blind, placebo-controlled clinical trials of modafinil are ongoing.

Modafinil promotes wakefulness and may cause insomnia. Clinicians are advised to avoid its use in patients with bipolar disorder or psychosis, as it may exacerbate symptoms of mania and psychosis. Nor should it be used in patients with left ventricular hypertrophy or mitral valve prolapse, as patients with these conditions developed potentially serious adverse effects in clinical trials.

Propranolol

The beta blocker propranolol has shown promise for the treatment of patients with severe cocaine withdrawal symptoms. Beta blockers are used primarily to treat angina and hypertension, but their primary pharmacological effect—reducing the impact of the neurotransmitter adrenaline—also reduces anxiety. The distressing anxiety and agitation experienced by cocaine-dependent patients during withdrawal appears to be due to heightened sensitivity to the effects of adrenaline and noradrenaline. For example, McDougle and colleagues (1994) demonstrated that giving cocaine-dependent patients yohimbine, a compound that increases adrenaline in the central nervous system, provoked significantly more anxiety during cocaine withdrawal. Along with potential efficacy against withdrawal-related anxiety, propranolol may lessen some of cocaine’s rewarding properties and more uncomfortable symptoms of craving. In a human laboratory trial, the beta blocker carvedilol reduced cocaine self-administration in non-treatment-seeking cocaine-dependent subjects (Sofuoglu et al., 2000).

Three clinical trials have suggested that propranolol may help patients with severe cocaine addiction to remain in treatment and to establish initial abstinence. In the first, a pilot trial in which participants knew what medication they were receiving, propranolol proved safe and was well-tolerated (Kampman et al., 1999). Compared with a historical control group, more propranolol-treated patients (80 vs. 47 percent) stayed in treatment throughout a 7-week outpatient program. In a subsequent double-blind, placebo-controlled trial, propranolol improved treatment retention and decreased cocaine use among 108 patients with severe cocaine withdrawal symptoms, as determined by a score of 27 or more on the CSSA (Kampman et al., 2001). In the most recent trial, propranolol appeared to promote abstinence from cocaine in a trial of 199 patients who entered treatment with severe cocaine withdrawal symptoms (Kampman et al., 2006). Among patients adherent to the study medications, about 24 percent of the propranolol-treated patients were abstinent from cocaine at week 10, as opposed to only 12.5 percent of placebo-treated patients.

Propranolol is usually well-tolerated. The main side effect is sedation. However, beta blockers are best avoided in patients with a history of cocaine-induced cardiac ischemia. Patients who have presented to a medical facility with complaints of chest pain associated with cocaine use have been excluded from all clinical trials of propranolol for cocaine dependence and should not be treated with propranolol.

RELAPSE PREVENTION

Once cocaine-dependent patients have attained a period of abstinence, a more difficult phase of treatment, relapse prevention, begins. Pharmacological strategies for relapse prevention aim to block cocaine-induced euphoria or reduce cocaine craving. New insights into the effects of cocaine on the brain reward system have led to the identification of several promising medications.

Cocaine causes euphoria and reinforcement by raising dopamine levels in the mesocortical reward system. One potential way to counterbalance this effect is to elevate mesocortical levels of gamma-aminobutyric acid (GABA), a neurotransmitter that pushes dopamine levels downward by inhibiting the activity of dopaminergic (dopamine-releasing) neurons. Preclinical trials have suggested that GABAergic compounds (i.e., compounds that promote GABA release or conservation) blunt the dopamine response to cocaine administration and conditioned reminders of prior cocaine use (Dewey et al., 1997) and reduce self-administration of cocaine in animal models (Kushner, Dewey, and Kornetsky, 1999). Accordingly, GABAergic medications are being tested as potential agents to prevent relapse by blocking cocaine-induced euphoria or reducing cue-induced craving caused by reminders of prior cocaine use. Some promising GABAergic medications include gamma-vinyl GABA (GVG), tiagabine, and topiramate.

Gamma-Vinyl GABA

GVG is an antiepileptic that elevates brain GABA concentrations by inhibiting an enzyme, GABA transaminase, that breaks down the neurotransmitter. In pre-clinical trials, GVG has reduced rodents’ self-administration of cocaine (Kushner, Dewey, and Kornetsky, 1999), amphetamine, and methamphetamine (Gerasimov et al., 1999).

GVG has demonstrated potential efficacy for the treatment of stimulant dependence in the two clinical trials, both open-label, that have addressed this question to date. Eight of 20 patients completed the first trial and reported drug-free periods ranging from 46 to 58 days (Brodie, Figuero, and Dewey, 2003). Eighteen of 30 subjects completed the second trial; 16 of the completers submitted drug tests negative for amphetamine and cocaine throughout the last 6 weeks of the trial (Brodie et al., 2005).

Although GVG is used in many countries, it has not been approved for use in the United States because of an association with visual field defects. Data suggest that this adverse effect occurs only after relatively long-term exposure, so brief treatments may be conducted safely (Schmitz et al., 2002). As a precaution, investigators in the second clinical trial of GVG for stimulant dependence used perimetry to assess for potential visual field defects; none occurred (Fechtner et al., 2006).

Although GVG is grouped here with medications to prevent relapse, it might be considered for abstinence initiation as well. The clinical trials cited earlier were conducted in patients who had not achieved sustained abstinence. Large-scale, well-controlled trials of GVG for both cocaine and amphetamine dependence are planned.

Topiramate

The pharmacological effects of topiramate appear particularly well-suited for preventing relapse to cocaine use. In addition to increasing cerebral levels of GABA and facilitating GABA neurotransmission (Kuzniecky et al., 1998), topiramate weakens the action of glutamate, a neurotransmitter that opposes GABA’s potentially therapeutic reduction of dopamine activity. Top-iramate’s exact mechanisms of action on GABA are not fully understood, but it is known to inhibit glutamate neurotransmission by blocking alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors (Gibbs et al., 2000). In animal models of cocaine relapse, blockade of AMPA receptors in the nucleus accumbens prevented reinstatement of cocaine self-administration (Cornish and Kalivas, 2000).

In a 13-week, double-blind, placebo-controlled pilot trial of topiramate involving 40 cocaine-dependent patients, those who received topiramate were more likely than controls who received placebo to be abstinent during the last 5 weeks of treatment (Kampman et al., 2004). Among patients who returned for at least one visit after receiving medications, more of those on topiramate achieved at least 3 weeks of continuous abstinence (59 vs. 26 percent), and more in this group were rated very much improved on the CGIS at their last visit (71 vs. 32 percent; Kampman et al., 2004).

Topiramate can cause sedation and memory problems, especially if the dose is titrated rapidly. Prescribing criteria contraindicate its use in patients with a history of kidney stones. Drug blood levels of patients with reduced renal function should be monitored, as the drug is excreted by the kidneys. Rare but serious complications of topiramate include metabolic acidosis, acute glaucoma, and oligohydrosis (decreased sweating).

Tiagabine

Tiagabine, a medication currently approved for treatment of seizures, raises brain GABA levels by selectively blocking the presynaptic GABA reuptake transporter type 1. Tiagabine was found to be well-tolerated and moderately effective for improving abstinence in a pilot study with 45 cocaine- and opiate-dependent patients participating in a methadone maintenance program (Gonzalez et al., 2003). In this 10-week trial, the number of urine samples free of cocaine metabolite increased by 33 percent in a group treated with 24 mg of tiagabine daily, while decreasing by 14 percent in a placebo-treated group.

Disulfiram

Disulfiram (Antabuse), a medication that is familiar to substance abuse clinicians as a treatment for alcohol dependence, is a promising cocaine relapse prevention medication with a unique mechanism of action. Disulfiram blocks the enzymatic degradation of cocaine and dopamine, leading to extremely high cocaine and dopamine levels when cocaine is ingested (McCance-Katz, Kosten, and Jatlow, 1998). However, rather than increase the cocaine-induced high, as one might expect, this effect makes the high less pleasant by increasing the associated anxiety. Four published trials have demonstrated that disulfiram reduces cocaine use in cocaine-dependent patients: Carroll et al., 1998 (cocaine- and alcohol-dependent patients); Carroll et al., 2004 (patients dependent on cocaine only); George et al., 2000 (cocaine- and opiate-dependent patients); Petrakis et al., 2000 (cocaine- and opiate-dependent patients).

Disulfiram is generally well-tolerated, although it may cause side effects, including sedation, headache, or a metallic taste in the mouth. If disulfiram is eventually approved for treating cocaine dependence, patients will need to be educated about its effects on cocaine metabolism and the potential danger of using disulfiram and the drug together. Patients also should be told that they may experience an unpleasant reaction (caused by the medication’s blockade of an enzyme, aldehyde dehydrogenase, and consequent buildup of acetaldehyde) if they drink alcohol. Disulfiram is contraindicated in patients who have severe myocardial disease or coronary occlusion; who have psychoses; and those who are receiving or those who have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing products.

TA-CD Vaccine

Another promising relapse prevention therapy currently being explored is a vaccine. TA-CD works by stimulating the production of cocaine-specific antibodies that bind to cocaine molecules and prevent them from crossing the blood–brain barrier, thereby blunting the drug’s euphoric and reinforcing effects. In laboratory trials, TA-CD decreased rodents’ self-administration of cocaine (Kantak et al., 2000).

The vaccine has shown promise in human trials. In one of the first, TA-CD was administered to 34 cocaine-dependent inpatients. A series of three vaccinations resulted in high antibody titers, and the vaccine was well-tolerated (Kosten et al., 2002). More recently, two doses of TA-CD were tested in cocaine-dependent patients in a 12-week outpatient treatment program. Preliminary outcome data suggested that the vaccine reduced the euphoric effects of cocaine; the higher dose was associated with more cocaine abstinence compared with the lower dose (Martell et al., 2005).

MEDICATIONS FOR AMPHETAMINE DEPENDENCE

The search for medications to treat amphetamine and methamphetamine dependence started much more recently than that for cocaine treatment medications. Consequently, fewer medications have been tested. Similarities between the mechanisms of action of amphetamine and methamphetamine and those of cocaine suggest that the same medications may help with both dependencies. Hence, several of the medications that have been discussed are undergoing, or about to undergo, testing for methamphetamine dependence. For instance, trials of topiramate and modafinil are planned.

Bupropion is an antidepressant medication that is also effective in smoking cessation. Bupropion’s efficacy for these uses rests upon its ability to support positive mood by inhibiting the reuptake of dopamine into cells, leaving more of the neurotransmitter circulating in the mesolimbic system. The same mechanism may be helpful in easing the negative mood symptoms of methamphetamine withdrawal.

Although studies have shown bupropion to be ineffective in treating cocaine dependence, a recent clinical trial suggested that it may have promise for methamphetamine dependence. Among 151 methamphetamine-dependent patients, bupropion recipients had somewhat better abstinence outcomes compared with placebo recipients; the difference approached, but did not quite achieve, statistical significance. In a subgroup of patients whose methamphetamine use at baseline was less intensive, however, bupropion treatment was associated with significantly more weeks of abstinence (Elkashef et al., 2007).

Bupropion is fairly well-tolerated. Common side effects include insomnia, agitation, dry mouth, and nausea. This medication is contraindicated in patients with seizure disorders, current or prior diagnoses of bulimia or anorexia nervosa, or concurrent treatment with (or within 14 days of discontinuation of) monoamine oxidase inhibitors. Bupropion should not be used in patients detoxifying from alcohol or sedatives.

MEDICATIONS AND VOUCHER-BASED REINFORCEMENT THERAPY

Voucher-based reinforcement therapy (VBRT) is a behavioral treatment in which substance-dependent patients who achieve predetermined therapeutic goals receive vouchers redeemable for goods and services in the community. VBRT has been shown to be highly effective for helping cocaine-dependent patients achieve initial abstinence (Higgins et al., 1994). Several recent trials have indicated that VBRT may be a highly effective psychosocial treatment platform for enhancing the efficacy of medications for the treatment of cocaine dependence. For example, Kosten and colleagues (2003) gave desipramine, an antidepressant, or placebo with VBRT or a noncontingent voucher control to cocaine- and opiate-dependent patients who were being maintained on buprenorphine. The patients given either desipramine or VBRT increased their frequency of urine samples containing no abused drug more rapidly than patients given neither, and those treated with both desipramine and VBRT produced the most such samples of any group (Kosten et al., 2003). These findings contrast with those of trials in the 1980s, which demonstrated that desipramine in combination with standard psychosocial treatment was ineffective in this population.

In another double-blind trial, bupropion plus VBRT was found to be superior to bupropion or VBRT alone, or placebo, in promoting abstinence from cocaine (Poling et al., 2006). Similar results were reported for the combination of the serotonin reuptake inhibitor (SRI) citalopram and VBRT (Moeller et al., 2007). Like desipramine, SRIs have not been found to be consistently efficacious for the treatment of cocaine dependence when used in association with standard psychosocial treatment.

The best way to integrate effective medications and psychotherapies into a comprehensive plan for the treatment of stimulant dependence has yet to be determined. One can imagine a treatment course that begins with an abstinence initiation medication and contingency management, then switches to relapse prevention medications when the patient reaches some significant abstinence milestone. Alternatively, a patient might continue to receive an abstinence initiation medication that is at some point supplemented with either a relapse prevention medication that is slowly titrated upward or with TA-CD immunization. How long medication treatment should be continued is another unanswered question. Studies to address these questions are being considered, but, for now, there are no data.

CONCLUSIONS

Currently, no medications are approved by the Food and Drug Administration for the treatment of stimulant dependence. However, recent advances in understanding the processes involved in cocaine addiction have allowed researchers to identify several promising candidates (Table 2). Many of these medications have already shown promise in double-blind, placebo-controlled clinical trials, and virtually all of them are undergoing confirmatory testing. Behavioral and psychosocial treatments, especially VBRT, may augment the efficacy of medication for the treatment of stimulant dependence.

TABLE 2
Summary of Controlled Clinical Trials of Medications for Cocaine and Methamphetamine Dependence

Clinicians should be aware that all of the trials to date have been relatively small; therefore, the efficacy and safety of these medications have not been established definitively. In addition, most of the trials have included primarily men; thus, efficacy in women is even less well-established. Although no medications are currently proven to be effective, it is hoped that effective pharmacological treatments for stimulant dependence will soon become available.

REFERENCES

  • Alterman AI, et al. Prediction of attrition from day hospital treatment in lower socioeconomic cocaine-dependent men. Drug and Alcohol Dependence. 1996;40(3):227–233. [PubMed]
  • Baker DA, et al. Neuroadaptations in cystine–glutamate exchange underlie cocaine relapse. Nature Neuroscience. 2003;6(7):743–749. [PubMed]
  • Brodie JD, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55(2):122–125. [PubMed]
  • Brodie JD, Figuero E, Dewey SL. Treating cocaine addiction: From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse. 2003;50(3):261–265. [PubMed]
  • Carroll KM, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998;93(5):713–727. [PubMed]
  • Carroll KM, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry. 2004;61(3):264–272. [PubMed]
  • Cornish JL, Kalivas PW. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. Journal of Neuroscience. 2000;20(RC89):1–5. [PubMed]
  • Dackis CA. Modafinil for cocaine dependence Paper presented at the American Society of Addiction Medicine. Medical-Scientific Conference; Miami, FL. 2007.
  • Dackis CA, et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence. 2003;70(1):29–37. [PubMed]
  • Dackis CA, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30(1):205–211. [PubMed]
  • Dackis CA, O’Brien C. Glutamatergic agents for cocaine dependence. Annals of the New York Academy of Sciences. 2003;1003:328–345. [PubMed]
  • Dewey SL, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 1997;25(4):393–398. [PubMed]
  • Elkashef AM, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33(5):1162–1170. [PubMed]
  • Fechtner RD, et al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results. Archives of Ophthalmology. 2006;124(9):1257–1262. [PubMed]
  • George TP, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biological Psychiatry. 2000;47(12):1080–1086. [PubMed]
  • Gerasimov MR, et al. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse. 1999;34(1):11–19. [PubMed]
  • Gibbs JW, et al. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(Suppl 1):S10–S16. [PubMed]
  • Gonzalez G, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction. 2003;98(11):1625–1632. [PubMed]
  • Hart CL, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology. 2008;33(4):761–768. [PubMed]
  • Higgins ST, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Archives of General Psychiatry. 1994;51(7):568–576. [PubMed]
  • Kampman KM, et al. Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence. Addictive Behaviors. 1999;24(2):287–291. [PubMed]
  • Kampman KM, et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychology of Addictive Behaviors. 2001;15(1):52–59. [PubMed]
  • Kampman KM, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence. 2004;75(3):233–240. [PubMed]
  • Kampman KM, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug and Alcohol Dependence. 2006;85(2):129–137. [PubMed]
  • Kantak KM, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berlin) 2000;148(3):251–262. [PubMed]
  • Kosten T, et al. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine. 2002;20(7–8):1196–1204. [PubMed]
  • Kosten T, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine-maintained patients. Drug and Alcohol Dependence. 2003;70(3):315–325. [PubMed]
  • Kushner SA, Dewey SL, Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics. 1999;290(2):797–802. [PubMed]
  • Kuzniecky R, et al. Topiramate increases cerebral GABA in healthy humans. Neurology. 1998;51(2):627–629. [PubMed]
  • Malcolm R, et al. Modafinil and cocaine interactions. American Journal of Drug and Alcohol Abuse. 2006;32(4):577–587. [PubMed]
  • Martell BA, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry. 2005;58(2):158–164. [PubMed]
  • McCance-Katz E, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug and Alcohol Dependence. 1998;52(1):27–39. [PubMed]
  • McDougle CJ, et al. Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Archives of General Psychiatry. 1994;51(9):713–719. [PubMed]
  • Moeller FG, et al. Citalopram combined with behavioral treatment reduces cocaine use: A double-blind, placebo-controlled trial. American Journal on Drug and Alcohol Abuse. 2007;33(3):367–378. [PubMed]
  • Petrakis IL, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95(2):219–228. [PubMed]
  • Poling J, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry. 2006;63(2):219–228. [PubMed]
  • Schmitz B, et al. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study. Journal of Neurology. 2002;249(4):469–475. [PubMed]
  • Sofuoglu M, et al. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug and Alcohol Dependence. 2000;60(1):69–76. [PubMed]
  • Sofuoglu M, et al. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug and Alcohol Dependence. 2003;69(3):273–282. [PubMed]
  • Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1994–2004. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. DASIS Series: S-33, DHHS Publication No. (SMA) 06-4180.

Articles from Addiction Science & Clinical Practice are provided here courtesy of BioMed Central